DHR — Danaher Corporation

Danaher Corporation (DHR) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Sales: $6.3 billion, with core revenue growth of 3% year-over-year.
• Adjusted Diluted EPS: $1.94, up approximately 8% year-over-year.
• Free Cash Flow: $1.3 billion for the quarter, totaling $2.4 billion for the first half of the year, resulting in a free cash flow to net income conversion ratio of 124%.
• Gross Profit Margin: 57.6%; adjusted operating profit margin at 27.1%, down 20 basis points year-over-year.
• Core Revenue Growth (excluding respiratory testing): 4.5%, indicating a 150 basis point acceleration from Q1.

2. Strategic Updates and Business Highlights:

• Strong performance in life sciences, with the segment delivering its best quarter in years.
• Successful product launches, including the Biacore 8S SPR system and the novus V55 mass spectrometry system, enhancing competitive positioning.
• Acquisition of Masimo closed earlier than expected, expected to be accretive to EPS and strategic growth.
• Leica Biosystems announced the pending acquisition of StatLab, which is anticipated to strengthen its product offerings and support long-term growth.

3. Forward Guidance and Outlook:

• Full-Year Adjusted EPS Guidance: Raised to $8.45-$8.60 from $8.35-$8.55 due to better-than-expected Q2 performance and earlier Masimo acquisition closure.
• Third Quarter Revenue Growth Expectation: Approximately 2%-3%, with a 250 basis point headwind from respiratory testing.
• Full-Year Core Revenue Growth Outlook: Adjusted to 3%-4%, reflecting improved expectations in life sciences but a more conservative outlook for bioprocessing.

4. Bad News, Challenges, or Points of Concern:

• Bioprocessing Segment: Experienced low single-digit growth due to shipment delays for large chromatography resin orders, impacting revenue expectations for the second half of the year. This led to a downward adjustment in growth projections from high single digits to mid-single digits.
• Geographic Performance: Core revenues in developed markets declined slightly, affected by shipment timing and lower respiratory revenue.
• Academic Market Stability: Academic funding remains below normal levels, posing a challenge for growth in that segment.

5. Notable Q&A Insights:

• Customer Shipment Delays: Several large customers delayed resin shipments due to production schedule changes, impacting bioprocessing revenue. The company maintains confidence in underlying demand trends.
• Visibility and Demand: Management reassured that inventory levels are lower than in previous years, indicating robust market conditions despite shipment delays.
• Life Sciences Confidence: Improved biotech funding is translating into actual orders, with strong performance noted in the consumables business, particularly in MRD testing solutions.
• Future Growth: Management expressed optimism about the long-term outlook for bioprocessing and life sciences, citing ongoing demand for biologics and therapeutics, and a multi-year CapEx cycle anticipated to support growth.

This summary encapsulates the key points from Danaher Corporation's Q2 2026 earnings call, highlighting both the positive developments and challenges faced by the company.